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Abstract
Feasibility study:
Objectives:
(a) Refine a bespoke enhanced support intervention (ESI) (including self-help materials, intervention manual and
training) for implementation by community pharmacy (CP) staff to people with sub-threshold depression and
long-term conditions (LTCs) based upon evidence-supported interventions in primary care
(b) Develop and refine study procedures (recruitment strategies and set up, screening, participant recruitment,
assessment, suitability of outcome measures and data collection procedures) for testing in the pilot study phase
Design: A case series/qualitative study
Setting: UK community pharmacy
Population: Adults with long-term health conditions who screen-positive for depression but who do not reach the
threshold for DSM IV Moderate Depressive disorder
Intervention: Enhanced support intervention (ESI) delivered by an appropriately trained community pharmacy team
member involving four to six sessions over four months. ESI is a modified form of an intervention within the
collaborative care framework for sub-threshold depression validated in previous studies in UK primary care which
appears suitable for implementation in community settings.
Sample size: 20–30 participants
Outcomes: Study implementation (recruitment and attrition rates), quality of data collection at baseline and
4 months and ESI adherence (number of contacts, DNA and drop out) as per objectives 1a/b
Qualitative evaluation: Semi-structured interviews with up to 10 participants and ESI facilitators and focus group(s)
(range of pharmacy staff n = 8–10) will be conducted to explore the acceptability of the intervention and feasibility
of the study, training and study procedures.
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External pilot study:
Objectives:
(a) Quantify the flow of participants (eligibility, recruitment and follow-up rate)
(b) Evaluate proposed recruitment, assessment and outcome measure collection methods
(c) Examine the delivery of the enhanced support intervention in a community pharmacy setting (intervention
uptake, retention and dose) to inform process evaluation
(d) Process evaluation, using semi-structured interviews with participants across a range of socio-economic
settings, and pharmacy staff to explore the acceptability of the ESI within community pharmacy, elements of
the intervention that were considered useful (or not) and appropriateness of study procedures
Design: Pilot randomised controlled trial, including a prospective economic and qualitative evaluation
Setting: As above
Population: As above
Intervention: As above with adaptations post feasibility study
Comparator: Usual care
Sample size: 100 participants
Outcomes: Data will be used to estimate recruitment, intervention delivery and study completion rates as per
objectives 2a–d. Definitive estimates of the effectiveness of ESI will not be made.
Primary outcome: Depression severity (Patient Health Questionnaire 9) at four months.
Secondary outcomes: Patient acceptance, uptake and attrition. ICD10 depression status, anxiety (GAD 7), health-
related quality of life (SF-12v2) and health-state utility (EQ5D 3L) will be measured at four months.
Economic evaluation: The incremental cost per QALY will be calculated from both the NHS and societal
perspective.
Process evaluation: Using mixed methods, potential mediators/moderators of the intervention, the acceptability (to
participants and pharmacy staff), barriers and facilitators to the use of ESI in community pharmacy, and impact on
usual practice will be examined. Semi-structured interviews with approximately 30 study participants, 20 pharmacy
staff and eight GPs near participating pharmacies will be conducted.
Trial registration: ISRCTN: ISRCTN11290592
Protocol version number: Version 4.1 (dated 16th January 2018)
Study Sponsor Tees Esk and Wear Valleys NHS Foundation Trust
Background
Depression accounts for 4.3% of the global disease bur-
den and causes 63 million disability-adjusted life years
annually. It is the largest cause of disease burden of all
mental health problems and is set to become the highest
amongst all health problems by 2030 [1]. Two to three-
fold increase in the prevalence of depression is found
across the range of long-term conditions (LTCs) result-
ing in poorer outcomes, lower quality of life, a reduced
ability to self-manage, substantial increased cost [2] and
a significant contribution to health inequalities [3].
Sub-threshold depression, identified by a positive screen
on the Whooley questions [4] and between two and four
symptoms of depression, is highly prevalent and a major
risk factor for progression to major depression [5].
Sub-threshold depression has comparable rates of
associated excess mortality to major depression [6].
Estimates of the prevalence of sub-threshold depression
in community samples range from 1.4 to 17.9% [7] and
up to 20% in those people with LTCs. Clinical guidelines
recommend brief psychological support [8]; however,
psychological healthcare services struggle to meet
demands of major depression and over 80% of ‘below
threshold’ conditions remain untreated [9]. Psychological
interventions reduce depressive symptoms in this popu-
lation and reduce the incidence of major depression [10]
but are not commonly available. Adopting a public
health approach in at-risk groups such as those with
LTCs may be an alternative to standard health services
intervention; however, there is very limited evidence to
support implementation.
Community pharmacies are ideally placed to offer
opportunistic support to people with a range of health
problems including low mood [11]. The Healthy Living
Pharmacy programme is an example of extended roles of
pharmacy teams, delivering for example smoking cessation
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and weight management interventions, through new in-
novative training programmes. These programmes lend
support to the National Health Service (NHS) and Public
Health England’s Five Year Forward View [12] calling for a
radical upgrade in public health, including new partner-
ships that ‘break down barriers’ to support people with
multiple health problems. The Marmot Review on Health
Inequalities [13] recommended a focus on the mental
health of people with long-term health problems due to
the uneven socio-economic distribution and impact of
such co-morbidities. The content of behavioural change/
management approaches to sub-threshold depression
shares much with other public health interventions such as
smoking cessation or weight management (goal setting,
facilitated self-help and diary keeping). Therefore, these
interventions targeted at sub-threshold depression may
also be suited to delivery by those staff delivering other
public health behavioural change programmes. Given that
90% of people live within 20 min walk of their local phar-
macy, especially within areas of high social deprivation [14]
and with high rates of ‘footfall’ of people with LTCs,
community pharmacies have a unique position to offer
enhanced support for any co-morbid sub-threshold depres-
sion alongside other health promotion activities. High-
quality evidence is needed to inform the design and
delivery of such services. The Community Pharmacies
Mood Intervention Study (CHEMIST) seeks to adapt ‘what
works’ for people with sub-threshold depression in primary
care and examine if this can be translated to the important
public health setting of community pharmacy. This feasi-
bility and pilot randomised controlled trial (RCT) study
will address the potential for a behavioural change inter-
vention and associated study procedures to work in this
innovative public mental health setting in preparation for a
definitive RCT. If this public health intervention is shown
to have potential, a definitive RCT would also need to
examine the depression prevention value of the interven-
tion, which is of particular benefit to the individual, health-
care system and society [15].
Reviews of the literature indicate existing evidence is
not sufficiently robust, or experience sufficiently devel-
oped, to support a definitive trial at this stage in the
evolution of this public health intervention. CHEMIST
therefore has two sets of objectives. The first set of
objectives to be met in the feasibility phase is to refine
our intervention (enhanced support intervention [ESI])
and research procedures. The second set of objectives to
be met in the pilot RCT phase is to estimate study
recruitment, acceptability and retention.
Feasibility study objectives
a. Refine the bespoke enhanced support intervention
(ESI) (including self-help materials, intervention
manual and training) for implementation by
community pharmacy staff for use with people with
sub-threshold depression and LTCs based upon
evidence-supported interventions in primary care.
b. Develop and refine study procedures (community
pharmacy set-up and recruitment strategies;
participant screening, recruitment and assessment;
suitability of outcome measures; and data collection
procedures) for testing in the pilot RCT phase.
External pilot RCT objectives
a. Quantify the flow of participants (eligibility,
recruitment and follow-up rate).
b. Evaluate proposed recruitment, assessment and
outcome measure collection methods.
c. Examine the delivery of the ESI in a community
pharmacy setting (intervention uptake, retention
and dose) to inform the process evaluation.
d. Process evaluation, using semi-structured interviews
with participants, pharmacy staff and general
practitioners (GPs) across a range of socio-
economic settings to explore the acceptability of the
ESI within the community pharmacy setting,
elements of the intervention that were considered
useful (or not), and appropriateness of study
procedures.
Methods—feasibility study
Design
A case series study with nested qualitative evaluation.
Setting
Community pharmacies in the North of England
Study population
Inclusion criteria: Adults (18+) with sub-threshold
depression (screen positive with two to four depression
symptoms confirmed by a diagnostic assessment tool)
and one or more LTCs.
Exclusion criteria: People who have alcohol or drug
dependence, or cognitive impairment, or have bipolar
disorder/psychosis/psychotic symptoms, or are acutely
suicidal, or those currently in receipt of psychological
therapy.
Recruitment
Recruitment to sub-threshold depression studies within
community pharmacy is untested in the UK. Therefore,
a key objective of the feasibility study will be to refine
potential recruitment approaches to test in the external
pilot RCT. Three approaches will be used.
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1. Pharmacy recruitment. Potential participants will be
identified via medication use linked to LTC and/or
other pharmacy use. They will be provided with a
study information pack either directly, attached to
home delivery prescriptions or via pharmacy mail
outs.
2. Publicity recruitment. Posters will be placed in
community pharmacies, general practices and local
community settings advertising the study with a
central contact point for the study team. Interested
people will be invited to contact the study team
either by phone, email or via the study website.
3. Primary care recruitment. General practice (GP)
database searches will be used to identify potential
participants (those with one or more LTC) and the
study information pack will be mailed out by the
practices.
The study information pack will include an invitation
letter, a participant information sheet, a consent form, a
background information sheet and a stamped addressed
envelope for return to the study team.
These procedures will be refined in the feasibility
phase to facilitate use and evaluation in the pilot RCT.
Diagnostic confirmation
The Mini International Neuropsychiatric Interview
(MINI) [16] will be used to establish the presence or ab-
sence of depression symptoms and disorder (sub-thresh-
old/major depression). Diagnostic interviews will be
carried out by a trained researcher over the telephone.
Intervention
Enhanced support intervention (ESI): designed specific-
ally for those with sub-threshold depression and LTCs to
be delivered over four to six sessions in a 4-month
period. Sessions will be delivered via telephone or face
to face in the privacy of pharmacy consulting rooms.
The ESI will be adapted from training/treatment mate-
rials used in previous sub-threshold depression research
[17]. The ESI consists of four main elements.
1. Behavioural activation (BA) focussed self-help
support. A simple psychological approach focussed
upon identifying life changes that have a detrimental
impact on psychologically healthy activities and
scheduling to stay well. This will be facilitated by a
printed self-help workbook and supported by a
trained pharmacy staff member (ESI facilitator).
2. Proactive follow-up. Participants will be provided
with a BA self-help workbook and an ESI facilitator
would telephone/meet the participant at regular
intervals to support its use.
3. Symptom monitoring. The ESI facilitator will
monitor symptoms at each support session using
the depression scale from the Depression Anxiety
Stress Scale (DASS) which is widely used/validated
in a UK community context [18]. It is brief, simple
to score, with clear clinical cut off scores (non/
mild/moderate/severe).
4. Decision supported signposting. Scores on the
DASS will be used to guide decision-making by the
ESI facilitator, guided by supervision delivered by
clinical members of the study team. Where risk or
significant clinical deterioration is noted, the
participant would be supported to access more
formal healthcare interventions.
The ESI will be delivered by pharmacy support staff
(ESI facilitators) experienced in the delivery of extended
roles (such as smoking cessation using behavioural
change approaches) and/or training to Royal Society of
Public Health standard (Understanding Health Improve-
ment Level 2). Fidelity will be supported by ESI facilita-
tor manuals and comprehensive face-to-face training
adapted from those used in previous studies. In addition,
a bespoke competency assessment will be used (based
upon experience from previous studies) at the end of the
intervention training to ensure ESI facilitators are able
to support participants in the intervention. With partici-
pant consent, audio recordings of the intervention
support sessions will be undertaken. A random selection
of recordings (10–20%) across the different phases of the
intervention (early/late) will be collected from each ESI
facilitator and independently reviewed.
Outcome measures
Depression severity will be measured by the Patient
Health Questionnaire 9 (PHQ9) [19]. Widely used in
clinical trials and settings, the PHQ9 provides excellent
internal and external validity and specificity/sensitivity in
a UK population [20]. The PHQ9 would be the primary
outcome measure in a definitive RCT.
Secondary outcome measures will include prevention
of depression (PHQ9 less than 10), anxiety (GAD7) [21],
somatic symptoms (PHQ15) [22], quality of life
(SF-12v2) [23], health-state utility (EQ5D-3 L) [24] and
healthcare utilisation via an adapted version of the Adult
Service Use Schedule (AD-SUS).
Process measures
Moderators: depression severity (PHQ9), age of onset
(MINI), number of episodes (MINI), LTC and socioeco-
nomic status will be collected at baseline interview.
Mediators: number of contacts, level of activation using
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the Behavioural Activation for Depression Scale (BADS)
collected at treatment sessions [25].
Baseline demographic measures: DOB, ethnicity, edu-
cation level, socioeconomic status and sex.
Assessment and follow-up
Data will be collected at screening/eligibility, baseline
and four months post-baseline. Due to the nature of the
feasibility study, blinding to allocation is not possible.
Sample size
No formal sample size calculation has been under-
taken for the feasibility study. A sample size of 20–30
participants recruited will be sufficient to meet feasi-
bility phase objectives.
Outcomes and data analysis
As this is the feasibility phase, study implementation
(recruitment and attrition rates, quality of data collec-
tion) will be assessed at baseline and four months, along
with ESI adherence (number of contacts, DNA and drop
out), as per the feasibility objectives. Rates will be
reported descriptively.
Qualitative evaluation
In-depth interviews will be conducted with up to ten pa-
tient participants (purposively sampled across pharmacy
location and with a mix of LTCs, from different areas of
deprivation) to explore the acceptability of the content
and location of the ESI. Interviews with approximately
ten ESI facilitators will be conducted following training
and again at the end of the feasibility study. A focus
group will be conducted with pharmacy staff to explore
the feasibility and acceptability of the training, interven-
tion and study procedures.
Existing literature will be used to develop topic guides.
The Normalisation Process Theory (NPT) approach [26]
will be used to sensitise topic guides and provide a
framework for analysis and interpretation of data in
order to identify the barriers and facilitators to imple-
mentation. This approach has been used in previous
studies [27].
The analysis will inform adaptations to the interven-
tion materials, training and study procedures for the
pilot RCT.
Qualitative evaluation recruitment
Recruitment of patient participants for qualitative inter-
views will be included in the information and consent
process for the feasibility study.
Staff involved in CHEMIST particularly ESI facilitators
will be contacted directly by the study team by letter
and provided with the staff participant information sheet
and consent form. They will be provided with pre-paid
envelopes to return the documentation directly to the
study team. This process will be carried out independently
of the pharmacy to ensure it is free from coercion from
employers or co-workers. All data collected will be anon-
ymised by the qualitative research team prior to reporting
to ensure the confidentiality of participants.
Methods—external pilot study
Design
An external pilot RCT including nested process evalu-
ation and economic evaluation.
Setting
Community pharmacies in the North of England sam-
pled across quintiles of area-level deprivation.
Study population
As described in the feasibility study above.
Recruitment
Recruitment methods will include those described in the
feasibility study above, but with refinements following
learning from feasibility phase.
Outcome measures
As described in the feasibility study above but with the
exclusion of the PHQ15.
Assessment and follow-up
Participants will be offered the option of completing
baseline and follow-up questionnaires over the telephone
or via post. Due to the nature of the study, participants
and those delivering the intervention will be unblinded
to allocation. Researchers carrying out follow-up assess-
ments will be blinded to treatment allocation.
Intervention
As described in the feasibility study above but with
adaptations made following the feasibility study.
Comparator
The control group will be the usual primary care man-
agement of sub-threshold depression and other local
community provision.
Sample size
Sample size calculations are based on estimating attri-
tion and the standard deviation of the primary outcome.
Assuming 20% of participants are lost to follow-up with
a sample size of 100, then the 95% confidence interval
for this level of attrition will be the observed difference
± 8 percentage points (i.e. between 12 and 28%) (%) [28].
Hence, an external pilot trial of 100 participants should
ensure robust estimates of recruitment and follow-up in
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this population. Furthermore, an external pilot study of
80 measured subjects will provide robust estimates of
the standard deviation of the outcome measure in this
population to inform the sample size calculation for a
subsequent larger definitive fully powered trial [29].
Randomisation and allocation concealment
Individual independent randomisation will be used.
Randomisation will be carried out by the York Trials
Unit (YTU), University of York, online randomisation
service (URL:www.yorkrand.com/), independently of the
trial team. One hundred participants will be randomised
on a 1:1 basis to either the intervention group (50) or
control group (50) following completion of the baseline
interview.
Outcome and data storage and analysis
Outcome data will be stored securely at the Department
of Health Sciences, University of York, following strict
confidentiality and data storage standard operating pro-
cedures (SOPs) and protocols. Pilot RCT data will be
scanned and validated at the York Trials Unit as defined
by YTU SOPs and protocols. Data will be stored on the
YTU system and will be the responsibility of the Univer-
sity of York and sponsor (TEWV NHS FT) as set out in
a collaboration agreement. Requests for access to data
will be considered in line with YTU and sponsor SOPs.
The flow of participants through the trial will be de-
tailed in a CONSORT flow diagram (see Additional file 1).
The number of people screened, randomly assigned, re-
ceiving the intervention, completing the study protocol
and providing outcome data will be summarised overall
and by trial arm. The number of individuals withdrawing
from the intervention and/or the trial and any reasons
for withdrawal will be summarised by trial arm. To
quantify the acceptability of the intervention, the num-
ber of sessions attended will also be summarised. The
primary outcome of this study will be reported descrip-
tively by treatment arm using mean, standard deviation
(SD), 95% confidence intervals, median and 25th and
75th percentiles.
While the main aim of this study is to establish practi-
cality, feasibility, recruitment rates and key parameters
for the sample size in order to inform a full-scale trial,
and although it is unlikely that the small sample size will
result in effectiveness being established, we will none the
less test the primary outcome to mimic practice for
full-scale trial. Results from this analysis will be treated
as unreliable and interpreted with caution [30, 31].
The two groups will be compared for the primary out-
come (PHQ-9 at 4 months follow-up) using linear re-
gression with adjustment for important baseline
covariates. Estimates from the model and 95% CI will be
presented. We may also explore the impact of pharmacy
effects. The potential impact of ‘pharmacy effects’ will
be quantified using intraclass correlation coefficient
(ICC) estimates with 95% confidence intervals and the
average caseload per pharmacy ESI facilitator. All
secondary outcomes will be summarised descriptively by
treatment arm using mean, SD, 95% confidence inter-
vals, median, 25th and 75th percentiles for continuous
outcomes, and the number of events and percentages
for categorical data.
Health economics
The economic analysis will evaluate the feasibility of col-
lecting resource use and health-related quality of life
(HRQoL) data in people with long-term health condi-
tions and sub-threshold depression. It will enable us to
identify relevant resource use categories for the cost-ef-
fectiveness analysis and evaluate the feasibility and chal-
lenges of measuring costs and outcomes in the study
population. The feasibility of collecting intervention
costs and acquiring unit cost data for all resource use
categories will be assessed. The primary analysis will
focus on questionnaire completion rates and item-level
rates of missing data at each time point for both re-
source use questionnaire and quality of life instruments.
Also, the level of resource use and utility levels (and
quality-adjusted life years) will be presented for each
group. The feasibility of conducting a cost-effectiveness
analysis using resource use and quality of life instru-
ments data will be evaluated. A cost-utility analysis using
the EQ-5D-3L and SF-12v2 responses which will be con-
verted into utility scores using UK population algorithms
[32] will be conducted. Then, the area under the curve
approach will be used to calculate quality-adjusted life
years (QALYs) for both groups. To estimate the incre-
mental difference in costs and QALYs, a regression ap-
proach will be used which will control for baseline
characteristics of patients, particularly baseline utility.
The regression coefficient will provide the estimate of
the incremental difference in QALYs and costs between
the treatment and control arms. A bootstrap approach
will be used to get the confidence interval around the in-
cremental cost-effectiveness ratio. The results will be
presented on the cost-effectiveness plane and as
cost-effectiveness acceptability curve to evaluate the
probability of being cost-effective against the commonly
used willingness-to-pay threshold in the UK.
Process evaluation
As per UK MRC recommendations, a mixed methods
approach to process evaluation [33] will be used to con-
sider fidelity, implementation, mechanisms and context.
Descriptive statistics will be used to describe elements of
the intervention (participants, dose and intervention
content). The moderational analysis will examine
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baseline variables that may moderate outcomes such as
age, depression onset age, number of episodes and socio-
economic status. The mediational analysis will investi-
gate hypothesised mechanisms of change such as
number of sessions, content of scheduled contacts (from
pharmacy ESI facilitator records) and changes in activa-
tion (BADS) using established methodology [34]. As this
is an external pilot RCT, it is considerably underpowered
to undertake these evaluations so data will be summarised
and used to refine process evaluation design to inform a
future large-scale definitive RCT.
A process evaluation using qualitative methods will be
used to explore acceptability and important elements of
the intervention from the perspective of the participants.
A purposive sample of approximately 15 participants
who completed the intervention will be invited to par-
ticipate in a semi-structured interview (recruitment and
data collection will continue until category saturation
has been achieved). Sampling will ensure that partici-
pants with a range of age and gender are sampled and
from a range of socio-economic groups. The interviews
will explore the acceptability of case-finding for sub-
threshold depression, receiving the enhanced support
intervention (ESI) within a community pharmacy set-
ting, impact on relationship with general practice and
research procedures. A sample of participants who
dropped out (had less than two sessions) will also be in-
vited to participate in a semi-structured interview to ex-
plore reasons for drop out. It is likely approximately 15
interviews will be needed to achieve data saturation [35].
Sampling will be ensured in areas of higher
deprivation (i.e. bottom two quintiles of index of mul-
tiple deprivation (IMD)), to enable us to explore per-
spectives of people particularly from
lower socioeconomic status (SES). Perceptions of the ap-
propriateness of the intervention for people with poor
health literacy and from lower socioeconomic status
(SES) will be explored. All interviewees will be inter-
viewed at a time and place convenient to them (e.g. at
home, in the pharmacy, GP surgery or by telephone).
Interviews with patient participants will be conducted
after the primary outcome data has been collected.
Interviews with approximately 20 pharmacy staff
(across a broad range of pharmacy roles) will examine
acceptability and important elements of the interven-
tion, training and supervision, barriers/facilitators to
participation and implementation, and impact on phar-
macy practice.
Interviews with approximately eight local GPs will ex-
plore knowledge and perspectives of the intervention,
impact on routine practice and how this intervention
might be implemented in practice.
Semi-structured interviews offer opportunities to cover
in-depth, a range of topics relevant to the research
questions, whilst also allowing for exploration and prob-
ing of additional issues raised during the interviews. In-
terviews topic guides will vary by group; these may be
amended iteratively as interviews progress but will con-
tain core questions highlighted in the feasibility study.
Interviews will last up to an hour and will be digitally re-
corded with consent and transcribed verbatim, the tran-
scripts forming the data for analysis. Coding will be
undertaken independently by members of the qualitative
research team with meetings to ensure emerging codes
remain grounded in the original data. Initial analysis will
use the principles of constant comparison, which will
allow modification of the topic guides and analysis
across the data sets [34]. Further analysis will use the
principles of framework analysis and NPT [26].
Process evaluation—recruitment
Recruitment of patient participants will be as described
in the feasibility study above.
ESI facilitators will be provided with the staff partici-
pant information sheet and consent form upon comple-
tion of their intervention training. Remaining pharmacy
staff will be contacted by letter and provided with the
same study information. A reminder letter will be sent
once the intervention delivery has commenced in each
participating pharmacy. All pharmacy staff will be pro-
vided with pre-paid envelopes to return the consent
form directly to the study team. Processes will ensure
participation is confidential and free from any coercion
by employers or co-workers.
The GPs of recruited participants and GPs in partici-
pant identification sites will be contacted by letter and
invited to take part. They will be provided with a partici-
pant information sheet, consent form and pre-paid enve-
lope to return to the study team.
CHEMIST study governance
The study will be led by the Chief Investigator (DE) with
day-to-day management provided by the Trial Manager
(EL). There will be an independent Trial Steering Group
(TSG) and Data Monitoring and Ethics Committee
(DMEC) as per NIHR recommended constitution. The
sponsor will provide oversight and audit of the study as
per local standard operating procedures. Serious adverse
events will be collected and monitored as per local
standard operating procedures.
Protocol amendments will be managed via the Health
Research Authority, Research Ethics Committee and
sponsor approvals process during the study.
Dissemination
The study will be disseminated via peer-reviewed journals
and conference presentations. Plain English summaries
will be produced and distributed via partner stakeholders
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and to study participants. Results will be used to assess if
and how a fully powered RCT is practical.
Discussion
Community pharmacies are increasingly used to deliver
health promotion activities and have regular contact
with people with long-term health conditions. The use
of community pharmacy in research, and in particular in
depression research, is new and as such requires testing
prior to conducting large scale randomised controlled
trial. The CHEMIST feasibility and pilot RCT study is
an innovative design in this novel area. The methods
outlined will produce data on how and if future trials
might be conducted and will be disseminated through
conference presentation and peer-reviewed open
access publication.
CHEMIST study status
At time of writing the CHEMIST study is still in its re-
cruitment phase and process evaluation has commenced.
Additional file
Additional file 1: CHEMIST pilot RCT consort flow chart. (DOCX 40 kb)
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